Press release
Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo® (Lenacapavir)
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced it has been awarded the prestigious 2025 Prix Galien USA Award
About this update from Gilead Sciences, Inc.
[{"type":"text","content":" FOSTER CITY, Calif.--(BUSINESS WIRE)--\nGilead Sciences, Inc. (Nasdaq: GILD) today announced it has been awarded the prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product for Yeztugo® (lenacapavir), the company’s twice-yearly injectable HIV-1 capsid inhibitor that provides adults and adolescents (≥35kg) at risk of HIV-1 acquisition with a new, highly effective option for pre-exposure prophylaxis (PrEP) for the prevention of HIV. The award, which recognizes outstanding pharmaceutical products for their contributions to improving human health, is a testament to Gilead’s long-standing commitment to HIV innovation.\n\n\nHIV continues to pose a formidable global health challenge, with 1.3 million new infections occurring each year—highlighting the critical need for innovative approaches in HIV prevention. Lenacapavir, developed over 17 years by Gilead teams, is a first-in-class antiretroviral that blocks multiple stages of the HIV life cycle, including nuclear entry and capsid assembly.\n\n\n“Twice-yearly Yeztugo is one of the most important breakthroughs of modern science and illustrates what’s possible when Gilead innovation, the unwavering commitment of our scientists and the intentional involvement of communities most affected by HIV around the world come together to help address unmet needs in HIV prevention,” said Daniel O’Day, Chairman and CEO of Gilead Sciences. “This Prix Galien Award honors not only the scientific and clinical trial innovation behind Yeztugo, but also its potential public health impact for countries and regions around the world.”\n\n\nThe Prix Galien USA Awards, established in 2007, recognize leading-edge scientific advances in life sciences that enhance human health globally. Awarded annually, the competition is judged by a prestigious committee comprised of Nobel laureates, industry leaders and distinguished individuals in the health sector. The category of Best Pharmaceutical Product is highly competitive, with this year’s nominees including 18 innovative medicines approved by the FDA within the past five years.\n\n\nThe Prix Galien USA Award is one of several recent accolades for Gilead and Yeztugo. For its work in HIV, the company was recently recognized on Fortune's Change the World list, while Yeztugo was chosen as one of TIME’s Best Inventions and named the 2024 Breakthrough of the...